A Two-part Randomized, Double-blind, Placebo-controlled Multicenter Dose Ranging and Confirmatory Study of the Safety and Efficacy of VAY736 in Autoimmune Hepatitis Patients With Incomplete Response to or Intolerance of Standard Therapy

Trial Profile

A Two-part Randomized, Double-blind, Placebo-controlled Multicenter Dose Ranging and Confirmatory Study of the Safety and Efficacy of VAY736 in Autoimmune Hepatitis Patients With Incomplete Response to or Intolerance of Standard Therapy

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs VAY 736 (Primary)
  • Indications Autoimmune hepatitis
  • Focus Therapeutic Use
  • Acronyms AMBER
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 17 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top